Saturday 17 October 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
262.03
5.90
−2.20%
Follow ILMN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 32.38% | 33.82% | 33.36% | 31.16% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 6 | 8 | 8 | |
| 12.95% | 13.39% | 13.13% | 11.52% | ||
ROIC |
17.46% | 17.69% | 19.55% | 23.22% | |
Return on Tangible Assets |
41.23% | 44.27% | 34.51% | 44.37% | |
Average Days of Receivables |
62.07 | 61.32 | 71.77 | 62.05 | |
Free Cash Flow per Share |
6.17 | 6.37 | 6.01 | 6.54 | |
Free Cash Flow |
931.00 | 974.00 | 931.00 | 1,000.00 | |
Capital Expenditures |
(164.00) | (154.00) | (148.00) | (122.00) | |
| Other line items | |||||
Cash ROIC |
16.94% | 18.30% | 15.93% | 21.49% | |
Accounts Receivable Turnover |
6.13 | 6.11 | 5.47 | 6.01 | |
Accounts Payable Turnover |
7.02 | 6.99 | 6.39 | 7.09 | |
Inventory Turnover |
2.51 | 2.59 | 2.65 | 2.49 | |
Average Days of Payables |
55.60 | 53.58 | 59.47 | 54.91 | |
Days of Inventory on Hand |
152.04 | 150.18 | 139.76 | 148.62 | |
Tax Rate |
(0.19) | (0.20) | (0.22) | (0.23) | |
Research and Development Expense of Revenue |
21.37% | 21.74% | 22.27% | 22.85% | |
Selling, General and Administrative Expense of Revenue |
25.15% | 24.83% | 25.01% | 24.37% | |
Share Based Compensation of Revenue |
5.92% | 5.96% | 6.33% | 6.79% | |
Interest Coverage |
8.92 | 8.52 | 7.99 | 7.71 | |
Operating CF/Net income |
1.33 | 1.32 | 1.27 | 1.60 | |
Depreciation/Fixed assets |
0.37 | 0.36 | 0.36 | 0.37 | |
Capex/Depreciation |
(0.60) | (0.57) | (0.55) | (0.44) | |
Revenue per Share |
29.76 | 28.71 | 28.02 | 28.03 | |
Operating CF per Share |
7.25 | 7.37 | 6.96 | 7.33 | |
Capex per Share |
(1.09) | (1.01) | (0.95) | (0.80) | |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.03 |
Columns are period end dates